虎头虎脑之鹰击长空的个人主页 - 老虎社区

虎头虎脑之鹰击长空

虎头虎脑之鹰击长空

暂无个人介绍

IP属地：江苏

189关注

8粉丝

0主题

0勋章

虎头虎脑之鹰击长空

2022-07-14

$商汤-W(00020)$不知为何，其实，长期还是可以看好的

虎头虎脑之鹰击长空

2022-06-29

$科济药业-B(02171)$支持支持

虎头虎脑之鹰击长空

2022-09-13

家庭已有一辆ES6，前日已锁单ET5

蔚来(09866)获德意志银行看好股价冲高逾16%领涨汽车板块

虎头虎脑之鹰击长空

2023-02-02

理想车真的理想？

抱歉，原内容已删除

虎头虎脑之鹰击长空

2022-12-30

哎

华兴资本：疫情影响Q4交付下调蔚来(NIO.US)目标价至10.4美元

虎头虎脑之鹰击长空

2022-12-15

悲观了一些

科济药业(02171)及药明巨诺(02126)齐挫瑞银指内地细胞疗法行业仍未成熟

虎头虎脑之鹰击长空

2022-12-15

目标价呢

*瑞银降科济药业-B(02171.HK)及药明巨诺-B(02126.HK)评级至“中性” 下调目标价

虎头虎脑之鹰击长空

2022-12-11

没有什么一帆风顺

抱歉，原内容已删除

虎头虎脑之鹰击长空

2022-11-19

$科济药业-B(02171)$ 亏啊

虎头虎脑之鹰击长空

2022-10-05

难啊

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"4098320575389210","uuid":"4098320575389210","gmtCreate":1635217855632,"gmtModify":1654832301518,"name":"虎头虎脑之鹰击长空","pinyin":"hthnzyjckhutouhunaozhiyingjichangkong","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/0cc990f6c7bc363a015b013ff9572be1","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":8,"headSize":189,"tweetSize":43,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":2,"name":"无畏虎","nameTw":"無畏虎","represent":"初生牛犊","factor":"发布3条非转发主帖,1条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-3","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"偶像虎友","description":"加入老虎社区1500天","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.12.05","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.10.23","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"228c86a078844d74991fff2b7ab2428d-2","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资总监虎","description":"证券账户累计交易金额达到30万美元","bigImgUrl":"https://static.tigerbbs.com/9d20b23f1b6335407f882bc5c2ad12c0","smallImgUrl":"https://static.tigerbbs.com/ada3b4533518ace8404a3f6dd192bd29","grayImgUrl":"https://static.tigerbbs.com/177f283ba21d1c077054dac07f88f3bd","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"80.73%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"35ec162348d5460f88c959321e554969-1","templateUuid":"35ec162348d5460f88c959321e554969","name":"精英交易员","description":"证券或期货账户累计交易次数达到30次","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.01.21","exceedPercentage":"60.25%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.06.11","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":3,"crmLevelSwitch":0,"location":"江苏","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":653715872,"gmtCreate":1681273876397,"gmtModify":1681273877883,"author":{"id":"4098320575389210","authorId":"4098320575389210","name":"虎头虎脑之鹰击长空","avatar":"https://static.tigerbbs.com/0cc990f6c7bc363a015b013ff9572be1","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4098320575389210","idStr":"4098320575389210"},"themes":[],"htmlText":"这个","listText":"这个","text":"这个","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/653715872","repostId":"2326119647","repostType":2,"repost":{"id":"2326119647","kind":"news","pubTimestamp":1681166841,"share":"https://www.laohu8.com/m/news/2326119647?lang=zh_CN&edition=full","pubTime":"2023-04-11 06:47","market":"us","language":"zh","title":"复宏汉霖(02696.HK)获复星医药增持14.86万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2326119647","media":"金融界网站","summary":"格隆汇4月11日丨根据联交所最新权益披露资料显示，2023年4月3日-4月4日，复宏汉霖(02696.HK)获Shanghai Fosun Pharmaceutical (Group) Co., Ltd.在场内以每股均价11.3422-11.9749港元合计增持14.86万股，涉资约173.25万港元。　　增持后，Shanghai Fosun Pharmaceutical (Group) Co., Ltd.最新持股数目为3430.92万股，持股比例由20.90%上升至20.99%。","content":"<html><body><div><p>　　格隆汇4月11日丨根据联交所最新权益披露资料显示，2023年4月3日-4月4日，<a href=\"https://laohu8.com/S/02696\">复宏汉霖</a>(02696.HK)获Shanghai Fosun Pharmaceutical (Group) Co., Ltd.在场内以每股均价11.3422-11.9749港元合计增持14.86万股，涉资约173.25万港元。</p><p>　　增持后，Shanghai Fosun Pharmaceutical (Group) Co., Ltd.最新持股数目为3430.92万股，持股比例由20.90%上升至20.99%。</p>\n<div>\n</div>\n</div></body></html>","source":"jinrongjie_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>复宏汉霖(02696.HK)获复星医药增持14.86万股</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n复宏汉霖(02696.HK)获复星医药增持14.86万股\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-04-11 06:47 北京时间&nbsp;&nbsp;&nbsp;<a href=http://hk.jrj.com.cn/2023/04/11064737465795.shtml><strong>金融界网站</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>格隆汇4月11日丨根据联交所最新权益披露资料显示，2023年4月3日-4月4日，复宏汉霖(02696.HK)获Shanghai Fosun Pharmaceutical (Group) Co., Ltd.在场内以每股均价11.3422-11.9749港元合计增持14.86万股，涉资约173.25万港元。　　增持后，Shanghai Fosun Pharmaceutical (Group) Co.,...</p>\n\n<a href=\"http://hk.jrj.com.cn/2023/04/11064737465795.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"600196":"复星医药","BK1161":"生物科技","BK1191":"制药","BK0188":"融资融券","BK1593":"医美概念股","BK0012":"证金概念","BK0175":"白马股","02196":"复星医药","BK0196":"行业龙头","BK0060":"抗癌","02696":"复宏汉霖","BK0187":"一线龙头","BK0096":"民营医院","BK0183":"MSCI概念","BK0028":"国家队","BK0239":"医药制造","BK1515":"抗疫概念"},"source_url":"http://hk.jrj.com.cn/2023/04/11064737465795.shtml","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2326119647","content_text":"格隆汇4月11日丨根据联交所最新权益披露资料显示，2023年4月3日-4月4日，复宏汉霖(02696.HK)获Shanghai Fosun Pharmaceutical (Group) Co., Ltd.在场内以每股均价11.3422-11.9749港元合计增持14.86万股，涉资约173.25万港元。　　增持后，Shanghai Fosun Pharmaceutical (Group) Co., Ltd.最新持股数目为3430.92万股，持股比例由20.90%上升至20.99%。","news_type":1,"symbols_score_info":{"600196":1,"02196":1,"02696":1}},"isVote":1,"tweetType":1,"viewCount":4462,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":659341894,"gmtCreate":1679794531918,"gmtModify":1679794533242,"author":{"id":"4098320575389210","authorId":"4098320575389210","name":"虎头虎脑之鹰击长空","avatar":"https://static.tigerbbs.com/0cc990f6c7bc363a015b013ff9572be1","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4098320575389210","idStr":"4098320575389210"},"themes":[],"htmlText":"呵呵","listText":"呵呵","text":"呵呵","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/659341894","repostId":"650770415","repostType":1,"repost":{"id":650770415,"gmtCreate":1679536800000,"gmtModify":1679541756533,"author":{"id":"3579560926082632","authorId":"3579560926082632","name":"投资界","avatar":"https://static.tigerbbs.com/6a09632062f91283b4308e641ec08979","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3579560926082632","idStr":"3579560926082632"},"themes":[],"title":"摩通传动宣布完成新一轮融资，国科投资领投","htmlText":"投资界3月23日消息，多轴伺服厂商摩通传动宣布完成近亿元A轮融资（此前2021年11月摩通传动已完成近亿元Pre-A轮融资），本轮融资由国科投资领投，老股东川商基金跟投。本轮融资资金将用于加大创新型产品研发投入、完善运控产品线、拓展新行业新市场等。 据悉，摩通传动是一家专注于工业伺服驱动系统、控制系统、I/O系统的国家高新技术企业，作为国内多轴伺服传动领域的开拓者和推动者，公司秉承“聚焦行业创新 赋能多轴场景”的理念，充分发挥技术优势，搭建起完整的工控（伺服、控制、传感）产品矩阵，矢志为工控领域打造最有竞争力的行业解决方案！","listText":"投资界3月23日消息，多轴伺服厂商摩通传动宣布完成近亿元A轮融资（此前2021年11月摩通传动已完成近亿元Pre-A轮融资），本轮融资由国科投资领投，老股东川商基金跟投。本轮融资资金将用于加大创新型产品研发投入、完善运控产品线、拓展新行业新市场等。 据悉，摩通传动是一家专注于工业伺服驱动系统、控制系统、I/O系统的国家高新技术企业，作为国内多轴伺服传动领域的开拓者和推动者，公司秉承“聚焦行业创新 赋能多轴场景”的理念，充分发挥技术优势，搭建起完整的工控（伺服、控制、传感）产品矩阵，矢志为工控领域打造最有竞争力的行业解决方案！","text":"投资界3月23日消息，多轴伺服厂商摩通传动宣布完成近亿元A轮融资（此前2021年11月摩通传动已完成近亿元Pre-A轮融资），本轮融资由国科投资领投，老股东川商基金跟投。本轮融资资金将用于加大创新型产品研发投入、完善运控产品线、拓展新行业新市场等。 据悉，摩通传动是一家专注于工业伺服驱动系统、控制系统、I/O系统的国家高新技术企业，作为国内多轴伺服传动领域的开拓者和推动者，公司秉承“聚焦行业创新 赋能多轴场景”的理念，充分发挥技术优势，搭建起完整的工控（伺服、控制、传感）产品矩阵，矢志为工控领域打造最有竞争力的行业解决方案！","images":[],"top":1,"highlighted":2,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/650770415","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":4325,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":650292563,"gmtCreate":1679286084252,"gmtModify":1679286085766,"author":{"id":"4098320575389210","authorId":"4098320575389210","name":"虎头虎脑之鹰击长空","avatar":"https://static.tigerbbs.com/0cc990f6c7bc363a015b013ff9572be1","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4098320575389210","idStr":"4098320575389210"},"themes":[],"htmlText":"看","listText":"看","text":"看","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/650292563","repostId":"650299881","repostType":1,"repost":{"id":650299881,"gmtCreate":1679282284000,"gmtModify":1679283442829,"author":{"id":"3578460021109326","authorId":"3578460021109326","name":"时代财经","avatar":"https://static.tigerbbs.com/91c2175656a070c51747405cb8325278","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3578460021109326","idStr":"3578460021109326"},"themes":[],"title":"专业技术+领先服务+持续创新：华泰财险深耕风险减量服务","htmlText":"本文来源：时代财经 作者：刘子琪 2023年1月15日，银保监会发布《关于财产保险业积极开展风险减量服务的意见》，首次从风险减量服务的服务领域、服务基础、服务内容、服务形式、依法合规、组织保障等多个维度，为保险公司深耕风险减量服务提供权威参考和指引。 2023年2月15日，银保监会召开全国财产保险监管工作会议，提出提出2023年要着力开展“风险减量”行动，做好前置减险、合规控险、精算计险、稽查化险、处置出险工作，提升“防”的能力、“减”的实效和“救”的服务。 多年来，华泰财险始终坚持通过专业技术、领先服务、持续创新，为企业客户提供风险减量控制的整体解决方案。目前华泰财险已探索出了一套推进风险减量管理的体系。 图片来源：图虫创意 一是组建专业团队。为了给客户提供更专业的服务，华泰财险组建了一支专业风控团队，团队实力雄厚，拥有国内外认证专家，以及各类细分领域专业人才。团队中有保险行业少有的NFPA（美国消防协会）认证的风控专家，以及遍布全国的兼职风控工程师20余人。 二是持续优化流程。在实际服务过程中，华泰财险不断梳理风险减量管理流程。每年年初，华泰财险会组织全国辖区内的分支机构提交年度防台防汛查勘清单，并结合客户企业规模、灾害风险等级、过往事故案件、往年查勘服务情况等综合因素制定年度服务计划。适时发布《年度汛期预警风控手册》，要求各机构及时督促客户企业提前开展准备工作。在主汛期来临前，华泰财险及时组织各地专项会议，制定并落实专项服务内容，同时要求全国辖区内的风控工程师走访客户企业现场，进行情况摸排，制定有针对性的专项服务计划，并取得显著效果。 此外，华泰财险积极应用创新科技，采用专业的软件工具，利用国际先进的自然灾害模拟软件、各类预警资讯发布平台，为客户企业提供实时、专业、全面的自然灾害风险预警和风险识别服务。华泰财险也与中再集团紧密合作，充分利用中再的专业平台，为客户企业","listText":"本文来源：时代财经 作者：刘子琪 2023年1月15日，银保监会发布《关于财产保险业积极开展风险减量服务的意见》，首次从风险减量服务的服务领域、服务基础、服务内容、服务形式、依法合规、组织保障等多个维度，为保险公司深耕风险减量服务提供权威参考和指引。 2023年2月15日，银保监会召开全国财产保险监管工作会议，提出提出2023年要着力开展“风险减量”行动，做好前置减险、合规控险、精算计险、稽查化险、处置出险工作，提升“防”的能力、“减”的实效和“救”的服务。 多年来，华泰财险始终坚持通过专业技术、领先服务、持续创新，为企业客户提供风险减量控制的整体解决方案。目前华泰财险已探索出了一套推进风险减量管理的体系。 图片来源：图虫创意 一是组建专业团队。为了给客户提供更专业的服务，华泰财险组建了一支专业风控团队，团队实力雄厚，拥有国内外认证专家，以及各类细分领域专业人才。团队中有保险行业少有的NFPA（美国消防协会）认证的风控专家，以及遍布全国的兼职风控工程师20余人。 二是持续优化流程。在实际服务过程中，华泰财险不断梳理风险减量管理流程。每年年初，华泰财险会组织全国辖区内的分支机构提交年度防台防汛查勘清单，并结合客户企业规模、灾害风险等级、过往事故案件、往年查勘服务情况等综合因素制定年度服务计划。适时发布《年度汛期预警风控手册》，要求各机构及时督促客户企业提前开展准备工作。在主汛期来临前，华泰财险及时组织各地专项会议，制定并落实专项服务内容，同时要求全国辖区内的风控工程师走访客户企业现场，进行情况摸排，制定有针对性的专项服务计划，并取得显著效果。 此外，华泰财险积极应用创新科技，采用专业的软件工具，利用国际先进的自然灾害模拟软件、各类预警资讯发布平台，为客户企业提供实时、专业、全面的自然灾害风险预警和风险识别服务。华泰财险也与中再集团紧密合作，充分利用中再的专业平台，为客户企业","text":"本文来源：时代财经 作者：刘子琪 2023年1月15日，银保监会发布《关于财产保险业积极开展风险减量服务的意见》，首次从风险减量服务的服务领域、服务基础、服务内容、服务形式、依法合规、组织保障等多个维度，为保险公司深耕风险减量服务提供权威参考和指引。 2023年2月15日，银保监会召开全国财产保险监管工作会议，提出提出2023年要着力开展“风险减量”行动，做好前置减险、合规控险、精算计险、稽查化险、处置出险工作，提升“防”的能力、“减”的实效和“救”的服务。 多年来，华泰财险始终坚持通过专业技术、领先服务、持续创新，为企业客户提供风险减量控制的整体解决方案。目前华泰财险已探索出了一套推进风险减量管理的体系。 图片来源：图虫创意 一是组建专业团队。为了给客户提供更专业的服务，华泰财险组建了一支专业风控团队，团队实力雄厚，拥有国内外认证专家，以及各类细分领域专业人才。团队中有保险行业少有的NFPA（美国消防协会）认证的风控专家，以及遍布全国的兼职风控工程师20余人。 二是持续优化流程。在实际服务过程中，华泰财险不断梳理风险减量管理流程。每年年初，华泰财险会组织全国辖区内的分支机构提交年度防台防汛查勘清单，并结合客户企业规模、灾害风险等级、过往事故案件、往年查勘服务情况等综合因素制定年度服务计划。适时发布《年度汛期预警风控手册》，要求各机构及时督促客户企业提前开展准备工作。在主汛期来临前，华泰财险及时组织各地专项会议，制定并落实专项服务内容，同时要求全国辖区内的风控工程师走访客户企业现场，进行情况摸排，制定有针对性的专项服务计划，并取得显著效果。 此外，华泰财险积极应用创新科技，采用专业的软件工具，利用国际先进的自然灾害模拟软件、各类预警资讯发布平台，为客户企业提供实时、专业、全面的自然灾害风险预警和风险识别服务。华泰财险也与中再集团紧密合作，充分利用中再的专业平台，为客户企业","images":[],"top":1,"highlighted":1,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/650299881","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":4583,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":650976473,"gmtCreate":1678870487792,"gmtModify":1678870489260,"author":{"id":"4098320575389210","authorId":"4098320575389210","name":"虎头虎脑之鹰击长空","avatar":"https://static.tigerbbs.com/0cc990f6c7bc363a015b013ff9572be1","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4098320575389210","idStr":"4098320575389210"},"themes":[],"htmlText":"谬","listText":"谬","text":"谬","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/650976473","repostId":"650947986","repostType":1,"repost":{"id":650947986,"gmtCreate":1678867395345,"gmtModify":1678867398540,"author":{"id":"3527667586584720","authorId":"3527667586584720","name":"小虎综合资讯","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3527667586584720","idStr":"3527667586584720"},"themes":[],"title":"区域银行股盘前继续走高，第一共和银行涨超16%","htmlText":"周三，美股区域银行股盘前继续走高，第一共和银行涨超16%，阿莱恩斯西部银行涨超9%，西太平洋合众银行(PACW.O)涨超2%。","listText":"周三，美股区域银行股盘前继续走高，第一共和银行涨超16%，阿莱恩斯西部银行涨超9%，西太平洋合众银行(PACW.O)涨超2%。","text":"周三，美股区域银行股盘前继续走高，第一共和银行涨超16%，阿莱恩斯西部银行涨超9%，西太平洋合众银行(PACW.O)涨超2%。","images":[{"img":"https://static.tigerbbs.com/7155ec30e580f2fba55041e0b95bf23e","width":"-1","height":"-1"},{"img":"https://static.tigerbbs.com/e9f59c0a15eb252bd476bd081c280209","width":"-1","height":"-1"},{"img":"https://static.tigerbbs.com/835932a46a1f0cbe1bd747674842a989","width":"-1","height":"-1"}],"top":1,"highlighted":1,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/650947986","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":3,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":4458,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":625375800,"gmtCreate":1676261733001,"gmtModify":1676261734853,"author":{"id":"4098320575389210","authorId":"4098320575389210","name":"虎头虎脑之鹰击长空","avatar":"https://static.tigerbbs.com/0cc990f6c7bc363a015b013ff9572be1","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4098320575389210","idStr":"4098320575389210"},"themes":[],"htmlText":"10078？不是8千多吗？","listText":"10078？不是8千多吗？","text":"10078？不是8千多吗？","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/625375800","repostId":"2311910691","repostType":2,"repost":{"id":"2311910691","kind":"news","pubTimestamp":1676260405,"share":"https://www.laohu8.com/m/news/2311910691?lang=zh_CN&edition=full","pubTime":"2023-02-13 11:53","market":"hk","language":"zh","title":"中国高端纯电更受欢迎！蔚来1月销量超过雷克萨斯，蔚来ET5销量超宝马3系","url":"https://stock-news.laohu8.com/highlight/detail?id=2311910691","media":"快科技","summary":"根据中汽中心最新终端零售数据，蔚来1月份表现出了强劲的竞争力，不仅 ET5在1月的上险量力压宝马3系，稳坐30万以上高端纯电车榜首，蔚来1月销量也超越了豪华品牌雷克萨斯和沃尔沃。“ET5在一年内的销量将超过宝马3系。”中汽中心数据表明，蔚来1月销量达到 10,078，超越二线外资品牌雷克萨斯的9,021台。","content":"<html><body><article><p>2023新年刚过，中国车市就初现格局变化。根据中汽中心最新终端零售数据，<a href=\"https://laohu8.com/S/NIO\">蔚来</a>1月份表现出了强劲的竞争力，不仅 ET5在1月的上险量力压宝马3系，稳坐30万以上高端纯电车榜首，<a href=\"https://laohu8.com/S/NIO.SI\">蔚来</a>1月销量也超越了<a href=\"https://laohu8.com/S/DLX\">豪华</a>品牌雷克萨斯和沃尔沃。有业内人士称，蔚来跻身豪华品牌第四，打破了中国汽车市场已延续了近二十年的豪华品牌座次，证明中国品牌在高端汽车市场越来越受欢迎，固化多年的市场格局终于发生了变化。</p><img src=\"https://fid-75186.picgzc.qpic.cn/20230213115415776d201y71lapf6ztl\"/><p>“ET5在一年内的销量将超过宝马3系。”在2022年成都车展上，蔚来汽车联合创始人、总裁秦力洪曾放出豪言，而在年底举办的NIO Day 2022上，蔚来创始人、董事长、CEO李斌又强调，对蔚来2023年销量超过雷克萨斯油车销量“非常有信心”。现在看，市场行情正在逐步印证两位高层的预判。</p><p>根据中汽中心数据，蔚来ET5的1月上险量达到近7,000台，在成交均价30万元以上中型车排名中超过宝马3系、宝马i3及奥迪一众车型，并与奔驰C级发生“缠斗”。具体来看，蔚来ET5一月上险量达到6,777台，超越宝马3系的6,495台，与奔驰C级7,173台也较为接近。</p><img src=\"https://fid-75186.picgzc.qpic.cn/20230213115421245d2011lqvtcogt3p\"/><p>从高端品牌整体销量上来看，以BBA为首的传统豪华油车正在发生下滑，而以蔚来为代表的高端纯电品牌则保持增长，甚至有“蚕食”油车份额的趋势。中汽中心数据表明，蔚来1月销量达到 10,078，超越二线外资品牌雷克萨斯的9,021台。蔚来的表现，进一步说明中国品牌在高端市场受欢迎度越来越高。</p><p>另一方面，蔚来1月成交均价高达41.33万元，超越宝马、奥迪等。中国品牌在消费者心目中的“高端”形象也越来越深。</p><p>当前，中国高端汽车市场竞争激烈，电车“取代”油车的步伐正在加快。 随着“油转电”大趋势的加速，高端市场电车与油车之间的竞争还将持续加剧。随着蔚来对自身体系竞争力的持续提升，其在高端纯电领域还将不断增长，对高端油车形成的“蚕食”和“取代”作用也将愈发明显。</p></article></body></html>","source":"tencent","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>中国高端纯电更受欢迎！蔚来1月销量超过雷克萨斯，蔚来ET5销量超宝马3系</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n中国高端纯电更受欢迎！蔚来1月销量超过雷克萨斯，蔚来ET5销量超宝马3系\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-02-13 11:53 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20230213115422825b9448&s=b><strong>快科技</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>2023新年刚过，中国车市就初现格局变化。根据中汽中心最新终端零售数据，蔚来1月份表现出了强劲的竞争力，不仅 ET5在1月的上险量力压宝马3系，稳坐30万以上高端纯电车榜首，蔚来1月销量也超越了豪华品牌雷克萨斯和沃尔沃。有业内人士称，蔚来跻身豪华品牌第四，打破了中国汽车市场已延续了近二十年的豪华品牌座次，证明中国品牌在高端汽车市场越来越受欢迎，固化多年的市场格局终于发生了变化。“ET5在一年内的...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20230213115422825b9448&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK1588":"回港中概股","09866":"蔚来-SW","BK1119":"汽车制造商","NIO":"蔚来"},"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20230213115422825b9448&s=b","is_english":false,"share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","article_id":"2311910691","content_text":"2023新年刚过，中国车市就初现格局变化。根据中汽中心最新终端零售数据，蔚来1月份表现出了强劲的竞争力，不仅 ET5在1月的上险量力压宝马3系，稳坐30万以上高端纯电车榜首，蔚来1月销量也超越了豪华品牌雷克萨斯和沃尔沃。有业内人士称，蔚来跻身豪华品牌第四，打破了中国汽车市场已延续了近二十年的豪华品牌座次，证明中国品牌在高端汽车市场越来越受欢迎，固化多年的市场格局终于发生了变化。“ET5在一年内的销量将超过宝马3系。”在2022年成都车展上，蔚来汽车联合创始人、总裁秦力洪曾放出豪言，而在年底举办的NIO Day 2022上，蔚来创始人、董事长、CEO李斌又强调，对蔚来2023年销量超过雷克萨斯油车销量“非常有信心”。现在看，市场行情正在逐步印证两位高层的预判。根据中汽中心数据，蔚来ET5的1月上险量达到近7,000台，在成交均价30万元以上中型车排名中超过宝马3系、宝马i3及奥迪一众车型，并与奔驰C级发生“缠斗”。具体来看，蔚来ET5一月上险量达到6,777台，超越宝马3系的6,495台，与奔驰C级7,173台也较为接近。从高端品牌整体销量上来看，以BBA为首的传统豪华油车正在发生下滑，而以蔚来为代表的高端纯电品牌则保持增长，甚至有“蚕食”油车份额的趋势。中汽中心数据表明，蔚来1月销量达到 10,078，超越二线外资品牌雷克萨斯的9,021台。蔚来的表现，进一步说明中国品牌在高端市场受欢迎度越来越高。另一方面，蔚来1月成交均价高达41.33万元，超越宝马、奥迪等。中国品牌在消费者心目中的“高端”形象也越来越深。当前，中国高端汽车市场竞争激烈，电车“取代”油车的步伐正在加快。 随着“油转电”大趋势的加速，高端市场电车与油车之间的竞争还将持续加剧。随着蔚来对自身体系竞争力的持续提升，其在高端纯电领域还将不断增长，对高端油车形成的“蚕食”和“取代”作用也将愈发明显。","news_type":1,"symbols_score_info":{"NIO":0.9,"09866":0.9}},"isVote":1,"tweetType":1,"viewCount":4708,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":622156610,"gmtCreate":1675317895430,"gmtModify":1675317897465,"author":{"id":"4098320575389210","authorId":"4098320575389210","name":"虎头虎脑之鹰击长空","avatar":"https://static.tigerbbs.com/0cc990f6c7bc363a015b013ff9572be1","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4098320575389210","idStr":"4098320575389210"},"themes":[],"htmlText":"理想车真的理想？","listText":"理想车真的理想？","text":"理想车真的理想？","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/622156610","repostId":"2308981760","repostType":2,"isVote":1,"tweetType":1,"viewCount":5253,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":626323471,"gmtCreate":1673850816793,"gmtModify":1673850818499,"author":{"id":"4098320575389210","authorId":"4098320575389210","name":"虎头虎脑之鹰击长空","avatar":"https://static.tigerbbs.com/0cc990f6c7bc363a015b013ff9572be1","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4098320575389210","idStr":"4098320575389210"},"themes":[],"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/626323471","repostId":"2303826099","repostType":2,"repost":{"id":"2303826099","kind":"news","pubTimestamp":1673581680,"share":"https://www.laohu8.com/m/news/2303826099?lang=zh_CN&edition=full","pubTime":"2023-01-13 11:48","market":"sh","language":"zh","title":"港股异动 | 科济药业-B(02171)午前涨超12% 核心管线产品CT053在今年有望商业化","url":"https://stock-news.laohu8.com/highlight/detail?id=2303826099","media":"智通财经","summary":"智通财经APP获悉，科济药业-B午前涨超12%，截至发稿，涨12.29%，报19.74港元，成交额8656.07万港元。据悉，科济药业核心管线产品为CT053，被开发用于治疗失败的复发或难治性多发性骨髓瘤成年患者，可特异性识别BCMA，令CAR-T细胞能够有效靶向及去除在细胞表面携带BCMA的多发性骨髓瘤细胞。2022年10月18日，CT053新药上市申请获国家药监局受理；此外，CT053在北美正开展Ib/II期临床试验，预计2023年递交BLA。分析表示，CT053在今年有望商业化。","content":"<html><body><p>智通财经APP获悉，<a href=\"https://laohu8.com/S/02171\">科济药业-B</a>(02171)午前涨超12%，截至发稿，涨12.29%，报19.74港元，成交额8656.07万港元。</p><p>智通财经APP在《两款CAR-T领跑国内同行，估值仍处于底部的科济药业-B（02171）现补涨行情？》中指出，根据Frost&amp;Sullivan预测，2021年国内CAR-T疗法的市场规模约为人民币2亿元，未来在癌症患者增加、政策优惠、患者负担能力提高的推动下，2030年将增至289亿元，2022年至2030年的复合年增长率高达45.0%。</p><p>据悉，科济药业核心管线产品为CT053，被开发用于治疗失败的复发或难治性多发性骨髓瘤（R/RMM）成年患者，可特异性识别BCMA，令CAR-T细胞能够有效靶向及去除在细胞表面携带BCMA的多发性骨髓瘤细胞。2022年10月18日，CT053新药上市申请获国家药监局受理；此外，CT053在北美正开展Ib/II期临床试验，预计2023年递交BLA。分析表示，CT053在今年有望商业化。</p></body></html>","source":"stock_zhitongcaijing","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股异动 | 科济药业-B(02171)午前涨超12% 核心管线产品CT053在今年有望商业化</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股异动 | 科济药业-B(02171)午前涨超12% 核心管线产品CT053在今年有望商业化\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-01-13 11:48 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/861494.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，科济药业-B(02171)午前涨超12%，截至发稿，涨12.29%，报19.74港元，成交额8656.07万港元。智通财经APP在《两款CAR-T领跑国内同行，估值仍处于底部的科济药业-B（02171）现补涨行情？》中指出，根据Frost&Sullivan预测，2021年国内CAR-T疗法的市场规模约为人民币2亿元，未来在癌症患者增加、政策优惠、患者负担能力提高的推动下，...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/861494.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK1587":"次新股","BK1161":"生物科技","BK1574":"生物医药B类股","BK1585":"昨日强势股","02171":"科济药业-B"},"source_url":"http://www.zhitongcaijing.com/content/detail/861494.html","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2303826099","content_text":"智通财经APP获悉，科济药业-B(02171)午前涨超12%，截至发稿，涨12.29%，报19.74港元，成交额8656.07万港元。智通财经APP在《两款CAR-T领跑国内同行，估值仍处于底部的科济药业-B（02171）现补涨行情？》中指出，根据Frost&Sullivan预测，2021年国内CAR-T疗法的市场规模约为人民币2亿元，未来在癌症患者增加、政策优惠、患者负担能力提高的推动下，2030年将增至289亿元，2022年至2030年的复合年增长率高达45.0%。据悉，科济药业核心管线产品为CT053，被开发用于治疗失败的复发或难治性多发性骨髓瘤（R/RMM）成年患者，可特异性识别BCMA，令CAR-T细胞能够有效靶向及去除在细胞表面携带BCMA的多发性骨髓瘤细胞。2022年10月18日，CT053新药上市申请获国家药监局受理；此外，CT053在北美正开展Ib/II期临床试验，预计2023年递交BLA。分析表示，CT053在今年有望商业化。","news_type":1,"symbols_score_info":{"02171":1}},"isVote":1,"tweetType":1,"viewCount":3124,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":628784077,"gmtCreate":1673494460499,"gmtModify":1673494462652,"author":{"id":"4098320575389210","authorId":"4098320575389210","name":"虎头虎脑之鹰击长空","avatar":"https://static.tigerbbs.com/0cc990f6c7bc363a015b013ff9572be1","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4098320575389210","idStr":"4098320575389210"},"themes":[],"htmlText":"买","listText":"买","text":"买","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/628784077","repostId":"2302033490","repostType":2,"repost":{"id":"2302033490","kind":"news","pubTimestamp":1673316639,"share":"https://www.laohu8.com/m/news/2302033490?lang=zh_CN&edition=full","pubTime":"2023-01-10 10:10","market":"sh","language":"zh","title":"港股异动 | 康宁杰瑞制药-B(09966)升8% 旗下恩沃利首次参与医保国谈 机构上调公司收入预测","url":"https://stock-news.laohu8.com/highlight/detail?id=2302033490","media":"智通财经","summary":"智通财经APP获悉，康宁杰瑞制药-B继续回升，盘初触及14.46港元，创21年12月下旬以来新高。公司PD-L1单抗恩沃利首次参与医保谈判，华安证券预计，进入医保帮助恩沃利快速放量，整体降价影响较小。截至发稿，康宁杰瑞制药涨7.77%，报14.42港元，成交额0.58亿港元。日前，康宁杰瑞制药旗下产品恩沃利首次参与医保谈判，适应症为微卫星高度不稳定晚期结直肠癌。恩沃利为全球首个皮下注射PD-L1单抗。","content":"<html><body><p>智通财经APP获悉，<a href=\"https://laohu8.com/S/09966\">康宁杰瑞制药-B</a>(09966)继续回升，盘初触及14.46港元，创21年12月下旬以来新高。公司PD-L1单抗恩沃利首次参与医保谈判，<a href=\"https://laohu8.com/S/600909\">华安证券</a>预计，进入医保帮助恩沃利快速放量，整体降价影响较小。此前，浦银国际上调公司22E/23E/24E收入预测，主要反映恩沃利优于预期的销售成绩。截至发稿，康宁杰瑞制药涨7.77%，报14.42港元，成交额0.58亿港元。</p><p>日前，康宁杰瑞制药旗下产品恩沃利首次参与医保谈判，适应症为微卫星高度不稳定（MSI-H）晚期结直肠癌。恩沃利为全球首个皮下注射PD-L1单抗。华安证券表示，预计进入医保帮助恩沃利快速放量，整体降价影响较小。上月，浦银国际上调公司2022E/23E/24E收入预测至2.0亿/4.5亿/5.3亿元人民币，对应63%2022-24ECAGR，主要反映恩沃利单抗优于我们预期的销售成绩。给予目标价13.6港元，维持“买入”。</p></body></html>","source":"stock_zhitongcaijing","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股异动 | 康宁杰瑞制药-B(09966)升8% 旗下恩沃利首次参与医保国谈 机构上调公司收入预测</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股异动 | 康宁杰瑞制药-B(09966)升8% 旗下恩沃利首次参与医保国谈 机构上调公司收入预测\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-01-10 10:10 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/859503.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，康宁杰瑞制药-B(09966)继续回升，盘初触及14.46港元，创21年12月下旬以来新高。公司PD-L1单抗恩沃利首次参与医保谈判，华安证券预计，进入医保帮助恩沃利快速放量，整体降价影响较小。此前，浦银国际上调公司22E/23E/24E收入预测，主要反映恩沃利优于预期的销售成绩。截至发稿，康宁杰瑞制药涨7.77%，报14.42港元，成交额0.58亿港元。日前，康宁杰瑞制药旗下...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/859503.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK1161":"生物科技","BK1574":"生物医药B类股","09966":"康宁杰瑞制药-B"},"source_url":"http://www.zhitongcaijing.com/content/detail/859503.html","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2302033490","content_text":"智通财经APP获悉，康宁杰瑞制药-B(09966)继续回升，盘初触及14.46港元，创21年12月下旬以来新高。公司PD-L1单抗恩沃利首次参与医保谈判，华安证券预计，进入医保帮助恩沃利快速放量，整体降价影响较小。此前，浦银国际上调公司22E/23E/24E收入预测，主要反映恩沃利优于预期的销售成绩。截至发稿，康宁杰瑞制药涨7.77%，报14.42港元，成交额0.58亿港元。日前，康宁杰瑞制药旗下产品恩沃利首次参与医保谈判，适应症为微卫星高度不稳定（MSI-H）晚期结直肠癌。恩沃利为全球首个皮下注射PD-L1单抗。华安证券表示，预计进入医保帮助恩沃利快速放量，整体降价影响较小。上月，浦银国际上调公司2022E/23E/24E收入预测至2.0亿/4.5亿/5.3亿元人民币，对应63%2022-24ECAGR，主要反映恩沃利单抗优于我们预期的销售成绩。给予目标价13.6港元，维持“买入”。","news_type":1,"symbols_score_info":{"09966":1}},"isVote":1,"tweetType":1,"viewCount":4262,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":621500630,"gmtCreate":1672366173820,"gmtModify":1672366175422,"author":{"id":"4098320575389210","authorId":"4098320575389210","name":"虎头虎脑之鹰击长空","avatar":"https://static.tigerbbs.com/0cc990f6c7bc363a015b013ff9572be1","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4098320575389210","idStr":"4098320575389210"},"themes":[],"htmlText":"哎","listText":"哎","text":"哎","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/621500630","repostId":"2295799477","repostType":2,"isVote":1,"tweetType":1,"viewCount":3619,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":623356344,"gmtCreate":1671083372788,"gmtModify":1671083374670,"author":{"id":"4098320575389210","authorId":"4098320575389210","name":"虎头虎脑之鹰击长空","avatar":"https://static.tigerbbs.com/0cc990f6c7bc363a015b013ff9572be1","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4098320575389210","idStr":"4098320575389210"},"themes":[],"htmlText":"悲观了一些","listText":"悲观了一些","text":"悲观了一些","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/623356344","repostId":"2291034074","repostType":2,"isVote":1,"tweetType":1,"viewCount":4749,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":623364030,"gmtCreate":1671073869620,"gmtModify":1671073871163,"author":{"id":"4098320575389210","authorId":"4098320575389210","name":"虎头虎脑之鹰击长空","avatar":"https://static.tigerbbs.com/0cc990f6c7bc363a015b013ff9572be1","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4098320575389210","idStr":"4098320575389210"},"themes":[],"htmlText":"目标价呢","listText":"目标价呢","text":"目标价呢","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/623364030","repostId":"2291257557","repostType":2,"isVote":1,"tweetType":1,"viewCount":3107,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":629431254,"gmtCreate":1670740448479,"gmtModify":1670740450001,"author":{"id":"4098320575389210","authorId":"4098320575389210","name":"虎头虎脑之鹰击长空","avatar":"https://static.tigerbbs.com/0cc990f6c7bc363a015b013ff9572be1","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4098320575389210","idStr":"4098320575389210"},"themes":[],"htmlText":"没有什么一帆风顺","listText":"没有什么一帆风顺","text":"没有什么一帆风顺","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/629431254","repostId":"1130128155","repostType":4,"isVote":1,"tweetType":1,"viewCount":1729,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":629254828,"gmtCreate":1670568026664,"gmtModify":1670568028151,"author":{"id":"4098320575389210","authorId":"4098320575389210","name":"虎头虎脑之鹰击长空","avatar":"https://static.tigerbbs.com/0cc990f6c7bc363a015b013ff9572be1","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4098320575389210","idStr":"4098320575389210"},"themes":[],"htmlText":"牛","listText":"牛","text":"牛","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/629254828","repostId":"629325157","repostType":1,"repost":{"id":629325157,"gmtCreate":1670293458779,"gmtModify":1670293469116,"author":{"id":"3514329116425907","authorId":"3514329116425907","name":"小虎AV","avatar":"https://static.tigerbbs.com/162e12f8dcec770ec19f66f2abb0d5db","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3514329116425907","idStr":"3514329116425907"},"themes":[],"title":"马斯克回应被调侃有中国血统：这是一种恭维","htmlText":"\n \n \n  当地时间12月4日，美国知名说唱歌手Kanye West发帖称，他怀疑马斯克有一半中国血统。对此，马斯克回应称：“我认为这是一种恭维！”事实上，马斯克曾经调侃称自己可能有中国血统，还多次夸赞中国人聪明勤奋。[眼眼]<a href=\"https://laohu8.com/S/TSLA\">$特斯拉(TSLA)$</a> <a href=\"https://laohu8.com/S/TWTR\">$Twitter(TWTR)$</a>\n \n","listText":"当地时间12月4日，美国知名说唱歌手Kanye West发帖称，他怀疑马斯克有一半中国血统。对此，马斯克回应称：“我认为这是一种恭维！”事实上，马斯克曾经调侃称自己可能有中国血统，还多次夸赞中国人聪明勤奋。[眼眼]<a href=\"https://laohu8.com/S/TSLA\">$特斯拉(TSLA)$</a> <a href=\"https://laohu8.com/S/TWTR\">$Twitter(TWTR)$</a>","text":"当地时间12月4日，美国知名说唱歌手Kanye West发帖称，他怀疑马斯克有一半中国血统。对此，马斯克回应称：“我认为这是一种恭维！”事实上，马斯克曾经调侃称自己可能有中国血统，还多次夸赞中国人聪明勤奋。[眼眼]$特斯拉(TSLA)$ $Twitter(TWTR)$","images":[],"top":1,"highlighted":2,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/629325157","isVote":1,"tweetType":2,"object":{"id":"4cfdabbb523a4f89b5934cfc90f5060f","tweetId":"629325157","videoUrl":"https://1254107296.vod2.myqcloud.com/73ba5544vodgzp1254107296/76b0a42d243791576860304241/I5NFav5YiGsA.mp4","poster":"https://static.tigerbbs.com/2ad9954c7af4e75b8c5b2e187f3d434a"},"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":3290,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":629628564,"gmtCreate":1670488638558,"gmtModify":1670488640378,"author":{"id":"4098320575389210","authorId":"4098320575389210","name":"虎头虎脑之鹰击长空","avatar":"https://static.tigerbbs.com/0cc990f6c7bc363a015b013ff9572be1","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4098320575389210","idStr":"4098320575389210"},"themes":[],"htmlText":"买","listText":"买","text":"买","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/629628564","repostId":"2289102853","repostType":2,"repost":{"id":"2289102853","kind":"news","pubTimestamp":1670380801,"share":"https://www.laohu8.com/m/news/2289102853?lang=zh_CN&edition=full","pubTime":"2022-12-07 10:40","market":"hk","language":"zh","title":"港股异动 | 商汤-W(00020)涨超14% 招银国际看好公司发展收入确定性更高的人工智能即服务模式 维持“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2289102853","media":"智通财经","summary":"智通财经APP获悉，商汤-W涨超14%，截至发稿，涨14.08%，报2.35港元，成交额8.73亿港元。消息面上，12月2日，商汤科技举办了年度投资者交流日。招银国际表示，公司AIDC需求端向好，带来云服务收入提升。该行看好平台化业务模式带来经常性服务收入，以及商汤发展收入确定性更高的人工智能即服务模式。同时，该行认为管理层自愿延长所持股份禁售期对投资者信心有一定提振作用，维持“买入”评级。","content":"<html><body><p>智通财经APP获悉，<a href=\"https://laohu8.com/S/00020\">商汤-W</a>(00020)涨超14%，截至发稿，涨14.08%，报2.35港元，成交额8.73亿港元。</p><p>消息面上，12月2日，商汤科技举办了年度投资者交流日。会上管理层重点介绍了智能汽车、智慧生活以及AIDC业务的商业化进展，同时对于美国禁止高端GPU出口新规，管理层表示短期内对产业影响可控，因限制的算力精度标称值高于现有的商用化AI应用。</p><p>招银国际表示，公司AIDC需求端向好，带来云服务收入提升。该行看好平台化业务模式带来经常性服务收入，以及商汤发展收入确定性更高的人工智能即服务（AIaaS）模式。同时，该行认为管理层自愿延长所持股份禁售期对投资者信心有一定提振作用，维持“买入”评级。</p></body></html>","source":"stock_zhitongcaijing","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股异动 | 商汤-W(00020)涨超14% 招银国际看好公司发展收入确定性更高的人工智能即服务模式 维持“买入”评级</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股异动 | 商汤-W(00020)涨超14% 招银国际看好公司发展收入确定性更高的人工智能即服务模式 维持“买入”评级\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-12-07 10:40 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/843316.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，商汤-W(00020)涨超14%，截至发稿，涨14.08%，报2.35港元，成交额8.73亿港元。消息面上，12月2日，商汤科技举办了年度投资者交流日。会上管理层重点介绍了智能汽车、智慧生活以及AIDC业务的商业化进展，同时对于美国禁止高端GPU出口新规，管理层表示短期内对产业影响可控，因限制的算力精度标称值高于现有的商用化AI应用。招银国际表示，公司AIDC需求端向好，带来...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/843316.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"161631":"人工智能","00020":"商汤-W"},"source_url":"http://www.zhitongcaijing.com/content/detail/843316.html","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2289102853","content_text":"智通财经APP获悉，商汤-W(00020)涨超14%，截至发稿，涨14.08%，报2.35港元，成交额8.73亿港元。消息面上，12月2日，商汤科技举办了年度投资者交流日。会上管理层重点介绍了智能汽车、智慧生活以及AIDC业务的商业化进展，同时对于美国禁止高端GPU出口新规，管理层表示短期内对产业影响可控，因限制的算力精度标称值高于现有的商用化AI应用。招银国际表示，公司AIDC需求端向好，带来云服务收入提升。该行看好平台化业务模式带来经常性服务收入，以及商汤发展收入确定性更高的人工智能即服务（AIaaS）模式。同时，该行认为管理层自愿延长所持股份禁售期对投资者信心有一定提振作用，维持“买入”评级。","news_type":1,"symbols_score_info":{"90006":1,"161631":1,"00020":1}},"isVote":1,"tweetType":1,"viewCount":2130,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":667288532,"gmtCreate":1668846107326,"gmtModify":1668846109200,"author":{"id":"4098320575389210","authorId":"4098320575389210","name":"虎头虎脑之鹰击长空","avatar":"https://static.tigerbbs.com/0cc990f6c7bc363a015b013ff9572be1","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4098320575389210","idStr":"4098320575389210"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/02171\">$科济药业-B(02171)$ &nbsp;</a>亏啊","listText":"<a href=\"https://laohu8.com/S/02171\">$科济药业-B(02171)$ &nbsp;</a>亏啊","text":"$科济药业-B(02171)$ 亏啊","images":[{"img":"https://static.tigerbbs.com/35cf5202174a1ae0a6e6923aa4a714ca","width":"1152","height":"2048"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/667288532","isVote":1,"tweetType":1,"viewCount":2466,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":667288899,"gmtCreate":1668845880412,"gmtModify":1668845882329,"author":{"id":"4098320575389210","authorId":"4098320575389210","name":"虎头虎脑之鹰击长空","avatar":"https://static.tigerbbs.com/0cc990f6c7bc363a015b013ff9572be1","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4098320575389210","idStr":"4098320575389210"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AAPL\">$苹果(AAPL)$ &nbsp;</a>","listText":"<a href=\"https://laohu8.com/S/AAPL\">$苹果(AAPL)$ &nbsp;</a>","text":"$苹果(AAPL)$","images":[{"img":"https://static.tigerbbs.com/af294fdf468789c2cf03a1e1c41bfc6a","width":"1152","height":"2445"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/667288899","isVote":1,"tweetType":1,"viewCount":2283,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":664161770,"gmtCreate":1667878225090,"gmtModify":1667878228368,"author":{"id":"4098320575389210","authorId":"4098320575389210","name":"虎头虎脑之鹰击长空","avatar":"https://static.tigerbbs.com/0cc990f6c7bc363a015b013ff9572be1","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4098320575389210","idStr":"4098320575389210"},"themes":[],"htmlText":"支持买入","listText":"支持买入","text":"支持买入","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/664161770","repostId":"2281956821","repostType":2,"repost":{"id":"2281956821","kind":"highlight","weMediaInfo":{"introduction":"凤凰网港股","home_visible":1,"media_name":"凤凰网港股","id":"1002821290","head_image":"https://static.tigerbbs.com/b6fb647077f1ce46dc341fc35c26e817"},"pubTimestamp":1667876221,"share":"https://www.laohu8.com/m/news/2281956821?lang=zh_CN&edition=full","pubTime":"2022-11-08 10:57","market":"us","language":"zh","title":"【券商聚焦】高盛维持科济药业-B(02171)“买入”评级 指CT053疗效或再受质疑","url":"https://stock-news.laohu8.com/highlight/detail?id=2281956821","media":"凤凰网港股","summary":"然而，在13.6个月的随访中，公司CT053 sCR/CR为78.6%，在更大样本和约7个月随访的sCR/CR率已回落到42.2%。该行认为，在更大的样本量下，sCR/CR率的下降可能会使Zevor-cel的疗效再次受到质疑。然而，在一期研究中，14名受试者中有4人在第52周达到了sCR，使得sCR/CR率从4.75个月随访的42.9%提高到13.6个月随访的78.6%。","content":"<html><body><p><a href=\"https://laohu8.com/S/GS\">高盛</a>发布研究报告指出，ASH(美国血液学会)2022报告中最新披露<a href=\"https://laohu8.com/S/02171\">科济药业-B</a>(02171)LUMMICAR-1(泽沃基奥仑赛注射液基于中国I/II期临床试验)研究的二期结果，该研究评估了CT053(现为Zevor-cel)在中国r/r MM(复发/难治 多发性骨髓瘤)患者中的疗效，其中，CT053的sCR/CR(严格完全缓解/完全缓解)较低，中位数为7个月。该行维持公司“买入”评级，目标价30.12港元。</p><p>该行指出，LUMMICAR-1研究中，一期招募了14名患者，二期招募了102名。在ASH 2021的报告中，该行注意到一些投资者最初担心，与<a href=\"https://laohu8.com/S/LEGN\">传奇生物</a>sCR -cel (严格完全缓解细胞疗法)12.4个月随访sCR/CR的67%相比，公司CT053约6个月的sCR率较低，为42.9%。然而，在13.6个月的随访中，公司CT053 sCR/CR为78.6%，在更大样本和约7个月随访的sCR/CR率已回落到42.2%。该行认为，在更大的样本量下，sCR/CR率的下降可能会使Zevor-cel的疗效再次受到质疑。然而，在一期研究中，14名受试者中有4人在第52周达到了sCR，使得sCR/CR率从4.75个月随访的42.9%提高到13.6个月随访的78.6%。二期研究长期随访中，额外的25-30例患者是否能达到sCR/CR仍有待观察。作为参考，在Ph1b/2 CARTITUDE-1研究(传奇生物西达基奥仑赛治疗研究)的3个月随访中，cilta-cel(嵌合抗原受体T细胞疗法)的sCR/CR率仅为29%。这表明，尽管第一次反应的中位随访时间约为1个月，但随着时间的推移，反应会加深。</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>【券商聚焦】高盛维持科济药业-B(02171)“买入”评级 指CT053疗效或再受质疑</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n【券商聚焦】高盛维持科济药业-B(02171)“买入”评级 指CT053疗效或再受质疑\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1002821290\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/b6fb647077f1ce46dc341fc35c26e817);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">凤凰网港股 </p>\n<p class=\"h-time\">2022-11-08 10:57</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p><a href=\"https://laohu8.com/S/GS\">高盛</a>发布研究报告指出，ASH(美国血液学会)2022报告中最新披露<a href=\"https://laohu8.com/S/02171\">科济药业-B</a>(02171)LUMMICAR-1(泽沃基奥仑赛注射液基于中国I/II期临床试验)研究的二期结果，该研究评估了CT053(现为Zevor-cel)在中国r/r MM(复发/难治 多发性骨髓瘤)患者中的疗效，其中，CT053的sCR/CR(严格完全缓解/完全缓解)较低，中位数为7个月。该行维持公司“买入”评级，目标价30.12港元。</p><p>该行指出，LUMMICAR-1研究中，一期招募了14名患者，二期招募了102名。在ASH 2021的报告中，该行注意到一些投资者最初担心，与<a href=\"https://laohu8.com/S/LEGN\">传奇生物</a>sCR -cel (严格完全缓解细胞疗法)12.4个月随访sCR/CR的67%相比，公司CT053约6个月的sCR率较低，为42.9%。然而，在13.6个月的随访中，公司CT053 sCR/CR为78.6%，在更大样本和约7个月随访的sCR/CR率已回落到42.2%。该行认为，在更大的样本量下，sCR/CR率的下降可能会使Zevor-cel的疗效再次受到质疑。然而，在一期研究中，14名受试者中有4人在第52周达到了sCR，使得sCR/CR率从4.75个月随访的42.9%提高到13.6个月随访的78.6%。二期研究长期随访中，额外的25-30例患者是否能达到sCR/CR仍有待观察。作为参考，在Ph1b/2 CARTITUDE-1研究(传奇生物西达基奥仑赛治疗研究)的3个月随访中，cilta-cel(嵌合抗原受体T细胞疗法)的sCR/CR率仅为29%。这表明，尽管第一次反应的中位随访时间约为1个月，但随着时间的推移，反应会加深。</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"02171":"科济药业-B"},"source_url":"http://hknews.szfuit.com/newRssInfo/feed?original_id=fc408ef70d3d60e37196dff3b518211e","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2281956821","content_text":"高盛发布研究报告指出，ASH(美国血液学会)2022报告中最新披露科济药业-B(02171)LUMMICAR-1(泽沃基奥仑赛注射液基于中国I/II期临床试验)研究的二期结果，该研究评估了CT053(现为Zevor-cel)在中国r/r MM(复发/难治 多发性骨髓瘤)患者中的疗效，其中，CT053的sCR/CR(严格完全缓解/完全缓解)较低，中位数为7个月。该行维持公司“买入”评级，目标价30.12港元。该行指出，LUMMICAR-1研究中，一期招募了14名患者，二期招募了102名。在ASH 2021的报告中，该行注意到一些投资者最初担心，与传奇生物sCR -cel (严格完全缓解细胞疗法)12.4个月随访sCR/CR的67%相比，公司CT053约6个月的sCR率较低，为42.9%。然而，在13.6个月的随访中，公司CT053 sCR/CR为78.6%，在更大样本和约7个月随访的sCR/CR率已回落到42.2%。该行认为，在更大的样本量下，sCR/CR率的下降可能会使Zevor-cel的疗效再次受到质疑。然而，在一期研究中，14名受试者中有4人在第52周达到了sCR，使得sCR/CR率从4.75个月随访的42.9%提高到13.6个月随访的78.6%。二期研究长期随访中，额外的25-30例患者是否能达到sCR/CR仍有待观察。作为参考，在Ph1b/2 CARTITUDE-1研究(传奇生物西达基奥仑赛治疗研究)的3个月随访中，cilta-cel(嵌合抗原受体T细胞疗法)的sCR/CR率仅为29%。这表明，尽管第一次反应的中位随访时间约为1个月，但随着时间的推移，反应会加深。","news_type":1,"symbols_score_info":{"02171":1}},"isVote":1,"tweetType":1,"viewCount":3193,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":665484950,"gmtCreate":1667444239271,"gmtModify":1667444262156,"author":{"id":"4098320575389210","authorId":"4098320575389210","name":"虎头虎脑之鹰击长空","avatar":"https://static.tigerbbs.com/0cc990f6c7bc363a015b013ff9572be1","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4098320575389210","idStr":"4098320575389210"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/01801\">$信达生物(01801)$</a>推荐","listText":"<a href=\"https://laohu8.com/S/01801\">$信达生物(01801)$</a>推荐","text":"$信达生物(01801)$推荐","images":[{"img":"https://static.tigerbbs.com/fc25faddbee63bd8dbf344b6e8346352","width":"1152","height":"2229"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/665484950","isVote":1,"tweetType":1,"viewCount":2473,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":665485201,"gmtCreate":1667444098703,"gmtModify":1667444100599,"author":{"id":"4098320575389210","authorId":"4098320575389210","name":"虎头虎脑之鹰击长空","avatar":"https://static.tigerbbs.com/0cc990f6c7bc363a015b013ff9572be1","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4098320575389210","idStr":"4098320575389210"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/06185\">$康希诺生物(06185)$</a>","listText":"<a href=\"https://laohu8.com/S/06185\">$康希诺生物(06185)$</a>","text":"$康希诺生物(06185)$","images":[{"img":"https://static.tigerbbs.com/41ebc7edc25d5d9f0b6fa624c6728589","width":"1152","height":"2229"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/665485201","isVote":1,"tweetType":1,"viewCount":646,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":668550213,"gmtCreate":1664970446133,"gmtModify":1664970447315,"author":{"id":"4098320575389210","authorId":"4098320575389210","name":"虎头虎脑之鹰击长空","avatar":"https://static.tigerbbs.com/0cc990f6c7bc363a015b013ff9572be1","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4098320575389210","idStr":"4098320575389210"},"themes":[],"htmlText":"难啊","listText":"难啊","text":"难啊","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/668550213","isVote":1,"tweetType":1,"viewCount":1997,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":688407274,"gmtCreate":1657776539802,"gmtModify":1704868244828,"author":{"id":"4098320575389210","authorId":"4098320575389210","name":"虎头虎脑之鹰击长空","avatar":"https://static.tigerbbs.com/0cc990f6c7bc363a015b013ff9572be1","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4098320575389210","authorIdStr":"4098320575389210"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/00020\">$商汤-W(00020)$</a>不知为何，其实，长期还是可以看好的","listText":"<a href=\"https://laohu8.com/S/00020\">$商汤-W(00020)$</a>不知为何，其实，长期还是可以看好的","text":"$商汤-W(00020)$不知为何，其实，长期还是可以看好的","images":[{"img":"https://static.tigerbbs.com/1ee1778608daf4f90e93e10e29e701cb","width":"1152","height":"2931"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":4,"repostSize":0,"link":"https://laohu8.com/post/688407274","isVote":1,"tweetType":1,"viewCount":6278,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"23574666724867","authorId":"23574666724867","name":"5e10d411","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"idStr":"23574666724867","authorIdStr":"23574666724867"},"content":"‌[笑哭] ‌这公司就是奇葩中的奇葩，每年亏得比赚的多好几倍，还不忘给高管发好几亿奖金，果然连薪酬都很软银~","text":"‌[笑哭] ‌这公司就是奇葩中的奇葩，每年亏得比赚的多好几倍，还不忘给高管发好几亿奖金，果然连薪酬都很软银~","html":"‌[笑哭] ‌这公司就是奇葩中的奇葩，每年亏得比赚的多好几倍，还不忘给高管发好几亿奖金，果然连薪酬都很软银~"},{"author":{"id":"3548442381649766","authorId":"3548442381649766","name":"海格微","avatar":"https://static.tigerbbs.com/627e959157d81f1d9d698bade03acc1d","crmLevel":1,"crmLevelSwitch":0,"idStr":"3548442381649766","authorIdStr":"3548442381649766"},"content":"一年营收47亿，一年亏损171亿，我看不出来长期价值在哪","text":"一年营收47亿，一年亏损171亿，我看不出来长期价值在哪","html":"一年营收47亿，一年亏损171亿，我看不出来长期价值在哪"}],"imageCount":1,"langContent":"CN","totalScore":0},{"id":683416732,"gmtCreate":1656467547028,"gmtModify":1704864867836,"author":{"id":"4098320575389210","authorId":"4098320575389210","name":"虎头虎脑之鹰击长空","avatar":"https://static.tigerbbs.com/0cc990f6c7bc363a015b013ff9572be1","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4098320575389210","authorIdStr":"4098320575389210"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/02171\">$科济药业-B(02171)$</a>支持支持","listText":"<a href=\"https://laohu8.com/S/02171\">$科济药业-B(02171)$</a>支持支持","text":"$科济药业-B(02171)$支持支持","images":[{"img":"https://static.tigerbbs.com/e9a37f609fa244c38a123c678dc9ba60","width":"1152","height":"2048"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/683416732","isVote":1,"tweetType":1,"viewCount":1291,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":663112431,"gmtCreate":1663036159323,"gmtModify":1663036160359,"author":{"id":"4098320575389210","authorId":"4098320575389210","name":"虎头虎脑之鹰击长空","avatar":"https://static.tigerbbs.com/0cc990f6c7bc363a015b013ff9572be1","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4098320575389210","authorIdStr":"4098320575389210"},"themes":[],"htmlText":"家庭已有一辆ES6，前日已锁单ET5","listText":"家庭已有一辆ES6，前日已锁单ET5","text":"家庭已有一辆ES6，前日已锁单ET5","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/663112431","repostId":"2267305635","repostType":2,"repost":{"id":"2267305635","kind":"highlight","weMediaInfo":{"introduction":"凤凰网港股","home_visible":1,"media_name":"凤凰网港股","id":"1002821290","head_image":"https://static.tigerbbs.com/b6fb647077f1ce46dc341fc35c26e817"},"pubTimestamp":1663033204,"share":"https://www.laohu8.com/m/news/2267305635?lang=zh_CN&edition=full","pubTime":"2022-09-13 09:40","market":"sh","language":"zh","title":"蔚来(09866)获德意志银行看好 股价冲高逾16%领涨汽车板块","url":"https://stock-news.laohu8.com/highlight/detail?id=2267305635","media":"凤凰网港股","summary":"汽车股多数向上，蔚来获德意志银行看好，冲高16.88%，报168.3港元。至于长城汽车涨2.28%，小鹏汽车涨1.75%，比亚迪股份涨1.62%。德意志银行发表报告指，监于客户对汽车的初步反应以及蔚来努力提高产量以满足需求，预计蔚来的ET5车将迅速成为最畅销的高端电动汽车。蔚来将于9月30日交付首批ET5。据称，蔚来已收到近20万张订单。我们预计2022年下半年将是汽车消费明确的高β窗口，行业盈利能力也望明显环比改善，坚定看好汽车板块下半年的投资机会。","content":"<html><body><p>汽车股多数向上，<a href=\"https://laohu8.com/S/NIO\">蔚来</a>(09866)获<a href=\"https://laohu8.com/S/DB\">德意志银行</a>看好，冲高16.88%，报168.3港元。至于<a href=\"https://laohu8.com/S/601633\">长城汽车</a>(02333)涨2.28%，<a href=\"https://laohu8.com/S/XPEV\">小鹏汽车</a>(09868)涨1.75%，<a href=\"https://laohu8.com/S/01211\">比亚迪股份</a>(01211)涨1.62%。<a href=\"https://laohu8.com/S/0H7D.UK\">德意志银行</a>发表报告指，监于客户对汽车的初步反应以及<a href=\"https://laohu8.com/S/NIO.SI\">蔚来</a>努力提高产量以满足需求，预计蔚来的ET5车将迅速成为最畅销的高端电动汽车。蔚来将于9月30日交付首批ET5。据称，蔚来已收到近20万张订单。该行又指，蔚来现有产品继续保持稳定的销售，表明强大的品牌力和服务;该行以蔚来为首选的中国电动车股，维持美股“买入”评级及39美元目标。<a href=\"https://laohu8.com/S/600030\">中信证券</a>指出，2022年8月汽车销量实现242万辆，环比-1.5%，同比+32.1%，同比大幅增长，符合预期。其中乘用车销量实现212.5万辆，环比-2.3%，同比+36.5%。商用车销量实现25.8万辆，环比+5%，同比+4%，从去年4月以来首次同比正增长。新能源汽车实现销量66.6万辆，同比+104.2%。我们预计2022年下半年将是汽车消费明确的高β窗口，行业盈利能力也望明显环比改善，坚定看好汽车板块下半年的投资机会。</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>蔚来(09866)获德意志银行看好 股价冲高逾16%领涨汽车板块</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n蔚来(09866)获德意志银行看好 股价冲高逾16%领涨汽车板块\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1002821290\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/b6fb647077f1ce46dc341fc35c26e817);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">凤凰网港股 </p>\n<p class=\"h-time\">2022-09-13 09:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>汽车股多数向上，<a href=\"https://laohu8.com/S/NIO\">蔚来</a>(09866)获<a href=\"https://laohu8.com/S/DB\">德意志银行</a>看好，冲高16.88%，报168.3港元。至于<a href=\"https://laohu8.com/S/601633\">长城汽车</a>(02333)涨2.28%，<a href=\"https://laohu8.com/S/XPEV\">小鹏汽车</a>(09868)涨1.75%，<a href=\"https://laohu8.com/S/01211\">比亚迪股份</a>(01211)涨1.62%。<a href=\"https://laohu8.com/S/0H7D.UK\">德意志银行</a>发表报告指，监于客户对汽车的初步反应以及<a href=\"https://laohu8.com/S/NIO.SI\">蔚来</a>努力提高产量以满足需求，预计蔚来的ET5车将迅速成为最畅销的高端电动汽车。蔚来将于9月30日交付首批ET5。据称，蔚来已收到近20万张订单。该行又指，蔚来现有产品继续保持稳定的销售，表明强大的品牌力和服务;该行以蔚来为首选的中国电动车股，维持美股“买入”评级及39美元目标。<a href=\"https://laohu8.com/S/600030\">中信证券</a>指出，2022年8月汽车销量实现242万辆，环比-1.5%，同比+32.1%，同比大幅增长，符合预期。其中乘用车销量实现212.5万辆，环比-2.3%，同比+36.5%。商用车销量实现25.8万辆，环比+5%，同比+4%，从去年4月以来首次同比正增长。新能源汽车实现销量66.6万辆，同比+104.2%。我们预计2022年下半年将是汽车消费明确的高β窗口，行业盈利能力也望明显环比改善，坚定看好汽车板块下半年的投资机会。</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"09866":"蔚来-SW","BK4574":"无人驾驶","DB":"德意志银行","BK4509":"腾讯概念","BK1588":"回港中概股","BK4532":"文艺复兴科技持仓","BK4581":"高盛持仓","BK4531":"中概回港概念","BK4099":"汽车制造商","BK4526":"热门中概股","BK4534":"瑞士信贷持仓","BK4555":"新能源车","BK4118":"综合性资本市场","BK4566":"资本集团","NIO":"蔚来","BK4505":"高瓴资本持仓","BK4504":"桥水持仓","NIO.SI":"蔚来","BK1119":"汽车制造商","BK4548":"巴美列捷福持仓","BK4552":"Archegos爆仓风波概念","EVS.SI":"MSCI China Electric Vehicles and Future Mobility ETF-NikkoAM"},"source_url":"http://hknews.szfuit.com/newRssInfo/feed?original_id=9bbf6d443c6a5a40eebfd04c6c69cc4f","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2267305635","content_text":"汽车股多数向上，蔚来(09866)获德意志银行看好，冲高16.88%，报168.3港元。至于长城汽车(02333)涨2.28%，小鹏汽车(09868)涨1.75%，比亚迪股份(01211)涨1.62%。德意志银行发表报告指，监于客户对汽车的初步反应以及蔚来努力提高产量以满足需求，预计蔚来的ET5车将迅速成为最畅销的高端电动汽车。蔚来将于9月30日交付首批ET5。据称，蔚来已收到近20万张订单。该行又指，蔚来现有产品继续保持稳定的销售，表明强大的品牌力和服务;该行以蔚来为首选的中国电动车股，维持美股“买入”评级及39美元目标。中信证券指出，2022年8月汽车销量实现242万辆，环比-1.5%，同比+32.1%，同比大幅增长，符合预期。其中乘用车销量实现212.5万辆，环比-2.3%，同比+36.5%。商用车销量实现25.8万辆，环比+5%，同比+4%，从去年4月以来首次同比正增长。新能源汽车实现销量66.6万辆，同比+104.2%。我们预计2022年下半年将是汽车消费明确的高β窗口，行业盈利能力也望明显环比改善，坚定看好汽车板块下半年的投资机会。","news_type":1,"symbols_score_info":{"09866":1,"DB":1,"EVS.SI":0.6,"NIO":1,"NIO.SI":0.6}},"isVote":1,"tweetType":1,"viewCount":3071,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":622156610,"gmtCreate":1675317895430,"gmtModify":1675317897465,"author":{"id":"4098320575389210","authorId":"4098320575389210","name":"虎头虎脑之鹰击长空","avatar":"https://static.tigerbbs.com/0cc990f6c7bc363a015b013ff9572be1","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4098320575389210","authorIdStr":"4098320575389210"},"themes":[],"htmlText":"理想车真的理想？","listText":"理想车真的理想？","text":"理想车真的理想？","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/622156610","repostId":"2308981760","repostType":2,"isVote":1,"tweetType":1,"viewCount":5253,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":621500630,"gmtCreate":1672366173820,"gmtModify":1672366175422,"author":{"id":"4098320575389210","authorId":"4098320575389210","name":"虎头虎脑之鹰击长空","avatar":"https://static.tigerbbs.com/0cc990f6c7bc363a015b013ff9572be1","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4098320575389210","authorIdStr":"4098320575389210"},"themes":[],"htmlText":"哎","listText":"哎","text":"哎","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/621500630","repostId":"2295799477","repostType":2,"repost":{"id":"2295799477","kind":"highlight","pubTimestamp":1672311553,"share":"https://www.laohu8.com/m/news/2295799477?lang=zh_CN&edition=full","pubTime":"2022-12-29 18:59","market":"us","language":"zh","title":"华兴资本：疫情影响Q4交付 下调蔚来(NIO.US)目标价至10.4美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2295799477","media":"智通财经网","summary":"华兴资本分析师Yiming Wang将蔚来(NIO.US)的目标价从12.30美元下调至10.40美元，并维持“持有”评级。","content":"<html><body><div> <p>智通财经APP获悉，华兴资本分析师Yiming  Wang将<a href=\"https://laohu8.com/S/NIO\">蔚来</a>(NIO.US)的目标价从12.30美元下调至10.40美元，并维持“持有”评级。Wang表示，新冠疫情造成的持续中断正在影响该公司第四季度的交付，导致交付指引下调。在<a href=\"https://laohu8.com/S/NIO.SI\">蔚来</a>下调交付指引后，该分析师下调了到2024年的预测。</p><p>早些时候，蔚来发布2022年第四季度交付量展望，预计四季度交付3.85万至3.95万辆汽车，较此前发布的4.3万至4.8万辆的展望有所下调，调整幅度为10%-18%。</p><p>截至发稿，蔚来盘前涨2.04%，报10.00美元。</p> <div></div> </div></body></html>","source":"highlight_zhitongcaijin","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>华兴资本：疫情影响Q4交付 下调蔚来(NIO.US)目标价至10.4美元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n华兴资本：疫情影响Q4交付 下调蔚来(NIO.US)目标价至10.4美元\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-12-29 18:59 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/854529.html><strong>智通财经网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，华兴资本分析师Yiming  Wang将蔚来(NIO.US)的目标价从12.30美元下调至10.40美元，并维持“持有”评级。Wang表示，新冠疫情造成的持续中断正在影响该公司第四季度的交付，导致交付指引下调。在蔚来下调交付指引后，该分析师下调了到2024年的预测。早些时候，蔚来发布2022年第四季度交付量展望，预计四季度交付3.85万至3.95万辆汽车，较此前发布的4.3万至...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/854529.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://img.zhitongcaijing.com/source/image/96015.jpg?x-oss-process=image/format,jpg/quality,Q_100/resize,h_300","relate_stocks":{"09866":"蔚来-SW","NIO":"蔚来"},"source_url":"http://www.zhitongcaijing.com/content/detail/854529.html","is_english":false,"share_image_url":"https://static.laohu8.com/6ca2dcdccfa2217fb20a0351f4efe814","article_id":"2295799477","content_text":"智通财经APP获悉，华兴资本分析师Yiming  Wang将蔚来(NIO.US)的目标价从12.30美元下调至10.40美元，并维持“持有”评级。Wang表示，新冠疫情造成的持续中断正在影响该公司第四季度的交付，导致交付指引下调。在蔚来下调交付指引后，该分析师下调了到2024年的预测。早些时候，蔚来发布2022年第四季度交付量展望，预计四季度交付3.85万至3.95万辆汽车，较此前发布的4.3万至4.8万辆的展望有所下调，调整幅度为10%-18%。截至发稿，蔚来盘前涨2.04%，报10.00美元。","news_type":1,"symbols_score_info":{"09866":1,"NIO":1}},"isVote":1,"tweetType":1,"viewCount":3619,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":623356344,"gmtCreate":1671083372788,"gmtModify":1671083374670,"author":{"id":"4098320575389210","authorId":"4098320575389210","name":"虎头虎脑之鹰击长空","avatar":"https://static.tigerbbs.com/0cc990f6c7bc363a015b013ff9572be1","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4098320575389210","authorIdStr":"4098320575389210"},"themes":[],"htmlText":"悲观了一些","listText":"悲观了一些","text":"悲观了一些","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/623356344","repostId":"2291034074","repostType":2,"repost":{"id":"2291034074","kind":"highlight","weMediaInfo":{"introduction":"凤凰网港股","home_visible":1,"media_name":"凤凰网港股","id":"1002821290","head_image":"https://static.tigerbbs.com/b6fb647077f1ce46dc341fc35c26e817"},"pubTimestamp":1671073866,"share":"https://www.laohu8.com/m/news/2291034074?lang=zh_CN&edition=full","pubTime":"2022-12-15 11:11","market":"us","language":"zh","title":"科济药业(02171)及药明巨诺(02126)齐挫 瑞银指内地细胞疗法行业仍未成熟","url":"https://stock-news.laohu8.com/highlight/detail?id=2291034074","media":"凤凰网港股","summary":"瑞银下调科济药业及药明巨诺目标价，盘中两只股份齐走低，其中科济药业为连续第三日回调，最新报15.2港元，跌3.92%，成交额894.15万港元；至于药明巨诺则跌6.55%，报4.42港元，成交额284.97万港元。该行指，随着产品Yescarta和Carteyva的推出，内地细胞疗法行业于去年崛起。但该行业仍未成熟，适应症批准有限，而且渗透度低。基于近期不利因素及高于预期的复发率，该行对内地细胞疗法行业看法不太正面，但长远而言仍保持乐观。","content":"<html><body><p>瑞银下调科济药业(02171)及药明巨诺(02126)目标价，盘中两只股份齐走低，其中科济药业为连续第三日回调，最新报15.2港元，跌3.92%，成交额894.15万港元；至于药明巨诺则跌6.55%，报4.42港元，成交额284.97万港元。瑞银发研报指，将<a href=\"https://laohu8.com/S/02171\">科济药业-B</a>评级由“买入”降至“中性”，2030财年销售预测由135亿元降至108亿元，目标价由34.5港元下调至18港元。将<a href=\"https://laohu8.com/S/02126\">药明巨诺-B</a>评级由“买入”降至“中性”，目标价由21港元降至5.5港元，销售预测也由45亿元降至34亿元，以反映低渗透度及未来CAR-T产品均价受压。该行指，随着产品Yescarta和Carteyva的推出，内地细胞疗法行业于去年崛起。但该行业仍未成熟，适应症批准有限，而且渗透度低。基于近期不利因素及高于预期的复发率，该行对内地细胞疗法行业看法不太正面，但长远而言仍保持乐观。</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>科济药业(02171)及药明巨诺(02126)齐挫 瑞银指内地细胞疗法行业仍未成熟</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n科济药业(02171)及药明巨诺(02126)齐挫 瑞银指内地细胞疗法行业仍未成熟\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1002821290\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/b6fb647077f1ce46dc341fc35c26e817);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">凤凰网港股 </p>\n<p class=\"h-time\">2022-12-15 11:11</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>瑞银下调科济药业(02171)及药明巨诺(02126)目标价，盘中两只股份齐走低，其中科济药业为连续第三日回调，最新报15.2港元，跌3.92%，成交额894.15万港元；至于药明巨诺则跌6.55%，报4.42港元，成交额284.97万港元。瑞银发研报指，将<a href=\"https://laohu8.com/S/02171\">科济药业-B</a>评级由“买入”降至“中性”，2030财年销售预测由135亿元降至108亿元，目标价由34.5港元下调至18港元。将<a href=\"https://laohu8.com/S/02126\">药明巨诺-B</a>评级由“买入”降至“中性”，目标价由21港元降至5.5港元，销售预测也由45亿元降至34亿元，以反映低渗透度及未来CAR-T产品均价受压。该行指，随着产品Yescarta和Carteyva的推出，内地细胞疗法行业于去年崛起。但该行业仍未成熟，适应症批准有限，而且渗透度低。基于近期不利因素及高于预期的复发率，该行对内地细胞疗法行业看法不太正面，但长远而言仍保持乐观。</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK1585":"昨日强势股","02171":"科济药业-B","BK1583":"高瓴概念","BK1587":"次新股","BK1161":"生物科技","BK1574":"生物医药B类股","02126":"药明巨诺-B"},"source_url":"http://hknews.szfuit.com/newRssInfo/feed?original_id=7c3ece7f4f1de68e57799c23b096af0c","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2291034074","content_text":"瑞银下调科济药业(02171)及药明巨诺(02126)目标价，盘中两只股份齐走低，其中科济药业为连续第三日回调，最新报15.2港元，跌3.92%，成交额894.15万港元；至于药明巨诺则跌6.55%，报4.42港元，成交额284.97万港元。瑞银发研报指，将科济药业-B评级由“买入”降至“中性”，2030财年销售预测由135亿元降至108亿元，目标价由34.5港元下调至18港元。将药明巨诺-B评级由“买入”降至“中性”，目标价由21港元降至5.5港元，销售预测也由45亿元降至34亿元，以反映低渗透度及未来CAR-T产品均价受压。该行指，随着产品Yescarta和Carteyva的推出，内地细胞疗法行业于去年崛起。但该行业仍未成熟，适应症批准有限，而且渗透度低。基于近期不利因素及高于预期的复发率，该行对内地细胞疗法行业看法不太正面，但长远而言仍保持乐观。","news_type":1,"symbols_score_info":{"02171":1,"02126":1}},"isVote":1,"tweetType":1,"viewCount":4749,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":623364030,"gmtCreate":1671073869620,"gmtModify":1671073871163,"author":{"id":"4098320575389210","authorId":"4098320575389210","name":"虎头虎脑之鹰击长空","avatar":"https://static.tigerbbs.com/0cc990f6c7bc363a015b013ff9572be1","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4098320575389210","authorIdStr":"4098320575389210"},"themes":[],"htmlText":"目标价呢","listText":"目标价呢","text":"目标价呢","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/623364030","repostId":"2291257557","repostType":2,"repost":{"id":"2291257557","kind":"highlight","pubTimestamp":1670985240,"share":"https://www.laohu8.com/m/news/2291257557?lang=zh_CN&edition=full","pubTime":"2022-12-14 10:34","market":"us","language":"zh","title":"*瑞银降科济药业-B(02171.HK)及药明巨诺-B(02126.HK)评级至“中性”  下调目标价","url":"https://stock-news.laohu8.com/highlight/detail?id=2291257557","media":"阿斯达克财经","summary":"(港股报价延迟最少十五分钟。沽空资料截至 2022-12-13 16:25。)","content":"<div>\n<p>(港股报价延迟最少十五分钟。沽空资料截至 2022-12-13 16:25。)</p>\n\n<a href=\"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1233118/latest-news/HK6\">网页链接</a>\n\n</div>\n","source":"aastocks_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>*瑞银降科济药业-B(02171.HK)及药明巨诺-B(02126.HK)评级至“中性”  下调目标价</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n*瑞银降科济药业-B(02171.HK)及药明巨诺-B(02126.HK)评级至“中性”  下调目标价\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-12-14 10:34 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1233118/latest-news/HK6><strong>阿斯达克财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(港股报价延迟最少十五分钟。沽空资料截至 2022-12-13 16:25。)</p>\n\n<a href=\"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1233118/latest-news/HK6\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20180119144849220_s.jpg","relate_stocks":{"02171":"科济药业-B","02126":"药明巨诺-B"},"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1233118/latest-news/HK6","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2291257557","content_text":"(港股报价延迟最少十五分钟。沽空资料截至 2022-12-13 16:25。)","news_type":1,"symbols_score_info":{"02171":1,"02126":1}},"isVote":1,"tweetType":1,"viewCount":3107,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":629431254,"gmtCreate":1670740448479,"gmtModify":1670740450001,"author":{"id":"4098320575389210","authorId":"4098320575389210","name":"虎头虎脑之鹰击长空","avatar":"https://static.tigerbbs.com/0cc990f6c7bc363a015b013ff9572be1","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4098320575389210","authorIdStr":"4098320575389210"},"themes":[],"htmlText":"没有什么一帆风顺","listText":"没有什么一帆风顺","text":"没有什么一帆风顺","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/629431254","repostId":"1130128155","repostType":4,"isVote":1,"tweetType":1,"viewCount":1729,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":667288532,"gmtCreate":1668846107326,"gmtModify":1668846109200,"author":{"id":"4098320575389210","authorId":"4098320575389210","name":"虎头虎脑之鹰击长空","avatar":"https://static.tigerbbs.com/0cc990f6c7bc363a015b013ff9572be1","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4098320575389210","authorIdStr":"4098320575389210"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/02171\">$科济药业-B(02171)$ &nbsp;</a>亏啊","listText":"<a href=\"https://laohu8.com/S/02171\">$科济药业-B(02171)$ &nbsp;</a>亏啊","text":"$科济药业-B(02171)$ 亏啊","images":[{"img":"https://static.tigerbbs.com/35cf5202174a1ae0a6e6923aa4a714ca","width":"1152","height":"2048"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/667288532","isVote":1,"tweetType":1,"viewCount":2466,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":668550213,"gmtCreate":1664970446133,"gmtModify":1664970447315,"author":{"id":"4098320575389210","authorId":"4098320575389210","name":"虎头虎脑之鹰击长空","avatar":"https://static.tigerbbs.com/0cc990f6c7bc363a015b013ff9572be1","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4098320575389210","authorIdStr":"4098320575389210"},"themes":[],"htmlText":"难啊","listText":"难啊","text":"难啊","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/668550213","isVote":1,"tweetType":1,"viewCount":1997,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}